Anticipate generic drug launch
Proactively manage your pharmacy inventory
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
|Abstract:||Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents H or C.sub.1-6 alkyl; R.sub.2 represents H or C.sub.1-6 alkyl; R.sub.3 represents H; R.sub.4 represents H or C.sub.1-3 alkyl; and pharmaceutically acceptable salts and solvates (for example hydrates thereof. The compounds are indicated as useful for the treatment of migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders. Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.|
|Inventor(s):||Oxford; Alexander W. (Royston, GB), Sutina; Darko (Arlesey, GB), Owen; Martin R. (Puckeridge, GB)|
|Assignee:||Glaxo Group Limited (GB2)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.